Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2009. The document serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data point disclosed is the price of $39.24 per American Depositary Receipt (ADR) at which a dividend reinvestment transaction occurred on January 8, 2009.
Material Changes
The filing reports a specific increase in the share interest of Dr. D. Pulman under the GlaxoSmithKline Executive Supplemental Savings Plan. This change resulted from the reinvestment of dividends paid on January 8, 2009, via the Annual Investment Plan feature. The transaction resulted in an interest of 28.26 ADRs.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is strictly a regulatory disclosure of a director's transaction in compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 9, 2009 (Notification date); January 8, 2009 (Dividend reinvestment date).
- Individual Involved: Dr. D. Pulman.
- Transaction Type: Increase in Ordinary share ADRs via dividend reinvestment.
- Transaction Price: $39.24 per ADR.
- Resulting Interest: 28.26 ADRs.